Hence, as a future step in therapeutic strategies against lipid-induced insulin resistance, specific PKD1 activators could be employed to coerce myocytes to specifically take up glucose for subsequent v-ATPase reassembly. This evidence concerns the gene PKD1 and Insulin resistance.